Clinical Trials Browser

Interventional × Neoplasms, Plasma Cell × LCL161 × Clear all

NCT03111992 2022-02-09

Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma

Phase 1 Completed

Hematologic Diseases, Multiple Myeloma, Neoplasms, Plasma Cell